Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | DHODH | Q02127 | 3/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732275 | 0.93 | LTA4H (0.33) | NOD1NOD2DHODHTNF | |
| SCHEMBL732984 | 0.91 | SCN9A (0.33) | NOD1NOD2GAAKMT2ASMN1; SMN2 | |
| SCHEMBL731686 | 0.91 | RAB9A (0.37) | PTGDR2NOD1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL733913 | 0.91 | PPARD (0.33) | NOD1NOD2 | |
| SCHEMBL733855 | 0.91 | NOD2 (0.31) | PTGDR2NOD1NOD2 | |
| SCHEMBL732630 | 0.89 | PTGDR2 (0.36) | PTGDR2NOD1NOD2GAAKMT2A | |
| SCHEMBL733921 | 0.89 | SCN9A (0.32) | DHODH | |
| SCHEMBL733186 | 0.89 | SCN9A (0.36) | PTGDR2NOD1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL731671 | 0.89 | MEN1 (0.37) | PTGDR2KMT2ARAB9ADHODHNR2F2 | |
| SCHEMBL733320 | 0.89 | EPAS1 (0.36) | PTGDR2NOD1NOD2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | claimed |
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | claimed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | claimed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | HRH2, HRH1, HRH4 | PTGDR2 16/4885NOD1 2768/4885NOD2 2545/4885 |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | PTGDR2 16/4885NOD1 2768/4885NOD2 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.